<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04771507</url>
  </required_header>
  <id_info>
    <org_study_id>HCK-LT-CLL02/2017</org_study_id>
    <nct_id>NCT04771507</nct_id>
  </id_info>
  <brief_title>A Pilot Study on Intermittent Ibrutinib in Patients With Advanced-phase Chronic Lymphocytic Leukemia (CLL)</brief_title>
  <acronym>IbruOnOff</acronym>
  <official_title>A Pilot Study on Intermittent and Repeated Dosing of Ibrutinib in the Treatment of Patients With Advanced-phase Chronic Lymphocytic Leukemia (CLL)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jeanette Lundin</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Karolinska University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Ibrutinib, an inhibitor of Bruton´s tyrosine kinase (BTK) is approved in CLL as continuous,&#xD;
      daily administration of 420 mg orally until progression. Ibrutinib drug costs in health care&#xD;
      are rapidly increasing and are difficult to predict, as long-term follow up analyses have&#xD;
      shown that many patients remain on therapy for several years, in some cases even many years.&#xD;
      It has been observed that patients who stop ibrutinib due to side effects may often remain&#xD;
      with continued CLL disease control i.e. in stable partial remission even when off ibrutinib&#xD;
      therapy. There are also emerging data on mutations within BTK, with loss of efficacy of&#xD;
      ibrutinib, during long-term continuous administration. These observations raise the question&#xD;
      whether alternative dosing strategies may be feasible. This pilot study will explore&#xD;
      intermittent and repeated dosing of ibrutinib, until alternative therapy is required due to&#xD;
      resistance or intolerance to ibrutinib. An &quot;ON-OFF&quot; dosing strategy will be applied, where&#xD;
      advanced-phase CLL patients who have received at least 6 months of ibrutinib and who have&#xD;
      achieved a stable PR will stop ibrutinib and be followed off therapy until clinical&#xD;
      progression, at which ibrutinib will be re-instituted. Such &quot;ON-OFF&quot; ibrutinib cycles may be&#xD;
      repeated until non-tolerability or resistance, or need of continuous dosing of ibrutinib&#xD;
      (i.e. early progression when off the drug). If successful, the study will indicate a way&#xD;
      forward towards reducing ibrutinib drug costs in health care without affecting long-term&#xD;
      disease control, possibly also with fewer ibrutinib-related side effects due to a lower&#xD;
      cumulative dose of ibrutinib. Long-term effects on potential mutations within BTK and its&#xD;
      downstream signaling molecules will also be analysed.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 23, 2018</start_date>
  <completion_date type="Anticipated">December 1, 2027</completion_date>
  <primary_completion_date type="Anticipated">April 1, 2023</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Patients treated with ibrutinib for at least 6 months and have achieved at least partial response will after inclusion stop the ibrutinib treatment and be followed-up for the study. If progress, they will re-initiate ibrutinib treatment. When they achieve at least partial response they stop the treatment again, and so on.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety measured as type, frequency and severity of adverse events.</measure>
    <time_frame>Through study completion, 1-24 months.</time_frame>
    <description>Type, frequency and severity of adverse events and relationship to intermittent ibrutinib dosing.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall response at each treatment cycle.</measure>
    <time_frame>Through study completion, 1-24 months.</time_frame>
    <description>Response when re-starting ibrutinib, at each cycle.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to PR and PR-L at each cycle.</measure>
    <time_frame>Through study completion, 1-24 months.</time_frame>
    <description>Time to partial response (PR) and partial response with persistent lymphocytosis (PR-L) when re-starting ibrutinib, at each cycle.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to stop until restart of ibrutinib due to progress</measure>
    <time_frame>Through study completion, 1-24 months.</time_frame>
    <description>Time from the patient going off ibrutinib until it has to be re-started due to progressive, for each cycle.disease (PD), at each cycle.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of ibrutinib treatment cycles and OFF therapy periods.</measure>
    <time_frame>Through study completion, 1-24 months.</time_frame>
    <description>The number of cycles each patient stop and re-start ibrutinib.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cumulative dose of ibrutinib.</measure>
    <time_frame>Through study completion, 1-24 months.</time_frame>
    <description>The cumulative dose of ibrutinib for each patient.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival.</measure>
    <time_frame>Through study completion, 1-24 months.</time_frame>
    <description>Overall survival.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Risk of early rebound phenomenon.</measure>
    <time_frame>Through study completion, 1-24 months.</time_frame>
    <description>Observation of early rebound phenomemon at each re-start of ibrutinib.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to need of alternative treatment.</measure>
    <time_frame>Through study completion, 1-24 months.</time_frame>
    <description>Time to need of alternative treatment.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Chronic Lymphocytic Leukemia</condition>
  <condition>Small Lymphocytic Lymphoma</condition>
  <arm_group>
    <arm_group_label>Intermittent ibrutinib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intermittent treatment with ibrutinib.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ibrutinib</intervention_name>
    <description>Ibrutinib will be stopped at inclusion in the and the patient will be followed OFF therapy. At clinical progress, ibrutinib will be restarted (ON period) at the same standard dose as used at inclusion. When the patient achieve at least partial response again, a new OFF period is started, and so on.</description>
    <arm_group_label>Intermittent ibrutinib</arm_group_label>
    <other_name>Imbruvica</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Ability to understand and voluntarily provide written informed consent and comply with&#xD;
             the requirements of the study.&#xD;
&#xD;
          2. Age 18 years and older. There is no upper age limit in this trial.&#xD;
&#xD;
          3. Able to adhere to the study visit schedule and other protocol requirements.&#xD;
&#xD;
          4. Before start ibrutinib for the first time: diagnosed with CLL/SLL and active disease&#xD;
             in need of treatment after having failed chemoimmunotherapy for CLL defined as a)&#xD;
             refractory according to iwCLL criteria; or b) relapsed and deemed not suitable for&#xD;
             additional chemo- or chemoimmunotherapy or c) del 17p and/or TP53 mutation&#xD;
             irrespective of prior therapy.&#xD;
&#xD;
          5. Having received at least 6 months of ibrutinib therapy and having achieved at least&#xD;
             clinical PR according to IWCLL criteria.&#xD;
&#xD;
          6. ECOG performance status of &lt;/= 2 at screening.&#xD;
&#xD;
          7. Laboratory test results:&#xD;
&#xD;
               -  Absolute neutrophil count &gt;/= 0.5 x 109/L&#xD;
&#xD;
               -  Platelet count &gt;/= 30 x 109/L&#xD;
&#xD;
               -  Serum creatinine &lt; 177 µmol/L&#xD;
&#xD;
               -  ASAT (SGOT) and ALAT (SGPT) &gt;/= 2 x ULN or &gt;/= 5 x ULN unless attributable to&#xD;
                  CLL/SLL&#xD;
&#xD;
          8. Disease free of prior malignancies for &gt;/= 2 years with exception of currently treated&#xD;
             basal cell, squamous cell carcinoma of the skin, or carcinoma &quot;in situ&quot; of the cervix&#xD;
             or breast.&#xD;
&#xD;
          9. Agree to use reliable forms of contraception. Post-menopausal females and surgically&#xD;
             sterilized females are exempt from this criterion.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Any serious medical condition, laboratory abnormality, or psychiatric illness that&#xD;
             would prevent the subject from signing the informed consent form.&#xD;
&#xD;
          2. Pregnant or breast feeding females.&#xD;
&#xD;
          3. Any condition, including the presence of laboratory abnormalities, which according to&#xD;
             the responsible physician places the subject at unacceptable risk if he/she were to&#xD;
             participate in the study or confounds the ability to interpret data from the study.&#xD;
&#xD;
          4. Use of any other experimental therapy within the last 14 days.&#xD;
&#xD;
          5. Concurrent use of other anti-cancer agents or treatments than ibrutinib (except a low&#xD;
             dose of corticosteroids, max 10 mg of prednisone/day).&#xD;
&#xD;
          6. Positivity for HIV or infectious hepatitis, type A, B or C.&#xD;
&#xD;
          7. Opportunistic infections within the last 3 months.&#xD;
&#xD;
          8. Patient planned for or being a potential candidate for allo-SCT.&#xD;
&#xD;
          9. Uncontrolled hemolytic anemia or autoimmune thrombocytopenia.&#xD;
&#xD;
         10. CNS involvement or history of Richter's transformation.&#xD;
&#xD;
         11. Requires or has received anticoagulation treatment with warfarin or equivalent Vitamin&#xD;
             K antagonists (eg, phenprocoumon) within 28 days of the first dose of ibrutinib.&#xD;
&#xD;
         12. Requires treatment with a strong cytochrome P450 (CYP) 3A4/5 inhibitor.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jeanette Lundin, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Karolinska University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jeanette Lundin, MD PhD</last_name>
    <phone>0700 85 67 86</phone>
    <phone_ext>46</phone_ext>
    <email>jeanette.lundin@sll.se</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Sanna Nyström, PhD</last_name>
    <phone>08 517 759 27</phone>
    <phone_ext>46</phone_ext>
    <email>sanna.nystrom@sll.se</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>St Olavs Hospital</name>
      <address>
        <city>Trondheim</city>
        <zip>7030</zip>
        <country>Norway</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Emadoldin Feyzi, MD PhD</last_name>
      <email>emadoldin.feyzi@stolav.no</email>
    </contact>
    <investigator>
      <last_name>Emadoldin Feyzi, MD PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Falu lasarett</name>
      <address>
        <city>Falun</city>
        <state>Dalarna</state>
        <zip>791 82</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Max Flogegård</last_name>
      <email>max.flogegard@ltdalarna.se</email>
    </contact>
    <investigator>
      <last_name>Max Flogegård, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Gävle Hospital</name>
      <address>
        <city>Gävle</city>
        <state>Gävleborg</state>
        <zip>801 87</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anders Uddevik, MD</last_name>
      <email>anders.uddevik@regiongavleborg.se</email>
    </contact>
    <investigator>
      <last_name>Anders Uddevik, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Skåne University Hospital</name>
      <address>
        <city>Lund</city>
        <state>Skåne</state>
        <zip>222 42</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jenny Klintman, MD</last_name>
      <email>jenny.klintman@skane.se</email>
    </contact>
    <investigator>
      <last_name>Jenny Klintman, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sahlgrenska University Hospital</name>
      <address>
        <city>Gothenburg</city>
        <zip>413 45</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Catharina Lewerin, MD PhD</last_name>
      <email>catharina.lewerin@vgregion.se</email>
    </contact>
    <investigator>
      <last_name>Catharina Lewerin, MD PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Karolinska University Hospital</name>
      <address>
        <city>Stockholm</city>
        <zip>17176</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jeanette Lundin, MD PhD</last_name>
      <email>jeanette.lundin@sll.se</email>
    </contact>
    <contact_backup>
      <last_name>Sanna Nyström, PhD</last_name>
      <email>sanna.nystrom@sll.se</email>
    </contact_backup>
    <investigator>
      <last_name>Jeanette Lundin, MD PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Norrland's University Hospital</name>
      <address>
        <city>Umeå</city>
        <zip>901 85</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Florentin Späth, MD PhD</last_name>
      <email>florentin.spaeth@umu.se</email>
    </contact>
    <investigator>
      <last_name>Floretin Späth, MD PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Akademiska hospital</name>
      <address>
        <city>Uppsala</city>
        <zip>751 85</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mattias Mattsson, MD</last_name>
      <email>mattias.mattsson@akademiska.se</email>
    </contact>
    <investigator>
      <last_name>Mattias Mattsson, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Örebro University Hospital</name>
      <address>
        <city>Örebro</city>
        <zip>701 85</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Magdalena Kättström, MD</last_name>
      <email>magdalena.kattstrom@regionorebrolan.se</email>
    </contact>
    <investigator>
      <last_name>Magdalena Kättström, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Norway</country>
    <country>Sweden</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>February 19, 2021</study_first_submitted>
  <study_first_submitted_qc>February 24, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">February 25, 2021</study_first_posted>
  <last_update_submitted>February 24, 2021</last_update_submitted>
  <last_update_submitted_qc>February 24, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 25, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Karolinska University Hospital</investigator_affiliation>
    <investigator_full_name>Jeanette Lundin</investigator_full_name>
    <investigator_title>Consultant, Associate Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Lymphoid</mesh_term>
    <mesh_term>Leukemia, Lymphocytic, Chronic, B-Cell</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

